Hemab Therapeutics Holdings Inc(COAG) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 23 at 4:00 PM ET (Korea 10/24 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 38.27% | Shs Outstand | 46.7M | Perf Week | 14.4% |
| Market Cap | 1.61B | Forward P/E | - | EPS next Y | 19.06% | Insider Trans | 19.93% | Shs Float | 28.8M | Perf Month | -3.7% |
| Enterprise Value | 1.15B | PEG | - | EPS next Q | -0.5 | Inst Own | 64.87% | Short Float | 11.75% | Perf Quarter | -31.73% |
| Income | - | P/S | - | EPS this Y | 95.48% | Inst Trans | 47% | Short Ratio | 7.35 | Perf Half Y | - |
| Sales | - | P/B | 3.54 | EPS next 5Y | 64.54% | ROA | - | Short Interest | 3.39M | Perf YTD | 27.41% |
| Book/sh | 9.73 | P/C | 3.51 | EPS past 3/5Y | - | ROE | - | 52W High | -37.93% ($55.42) | Perf Year | - |
| Cash/sh | 9.79 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 49.56% ($23.00) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 7.51% 7.54% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 2.62 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 35.85 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 50.32 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 35.85 | Sales Q/Q | - | SMA20 | 8.79% ($31.62) | Beta | - | Target Price | $61.71 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/11 | SMA50 | -12.3% ($39.22) | Rel Volume | 0.59 | Prev Close | $34.81 |
| Employees | 72 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -9.22% - | SMA200 | -6.25% ($36.69) | Avg Volume(3M) | 0.46M | Price | $34.4 |
| IPO | 2026/5/1 | Option/Short | No/Yes | Trades | 3237 | Volume | 271,181 | Change | -1.19% |
🩸 Hemab Therapeutics (COAG) is a clinical-stage biotech developing treatments for rare hereditary bleeding and clotting disorders. The company targets underserved coagulation disorders with limited existing treatment options, such as Glanzmann thrombasthenia and von Willebrand disease, and is advancing its next-generation antibody-based pipeline from bases in the United States and Europe.
Over the past 1 year, roughly in the middle
38% below its 1-year high.
Traded less than usual. That is 59% of its average volume.
Earnings are growing steadily
Earnings are expected to grow by +95.5% this year.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 64.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #114 of 595 in the industry
Based on market cap of $2B.
STOK#112 Stoke Therapeutics Inc $2B PER - 
NUVB#113 Nuvation Bio Inc $2B PER - COAG#114 Hemab Therapeutics Holdings Inc $2B PER - 
NVAX#115 Novavax Inc $2B PER - 
MESO#116 Mesoblast Ltd ADR $2B PER - 
FAQ
What kind of company is COAG?
COAG belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of COAG?
The market cap of COAG is approximately $1.6B, ranking 2,240 within its sector.
What is the 52-week high and low for COAG?
COAG has recorded a 52-week high of $55.42 and a low of $23.00.
